Concepts (103)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 9 | 2023 | 207 | 4.260 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2021 | 93 | 1.770 |
Why?
|
| Brain Neoplasms | 4 | 2023 | 1295 | 1.130 |
Why?
|
| Germinoma | 2 | 2023 | 31 | 0.970 |
Why?
|
| Immunological Synapses | 1 | 2025 | 32 | 0.870 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 61 | 0.870 |
Why?
|
| Cochlea | 1 | 2024 | 88 | 0.840 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 127 | 0.830 |
Why?
|
| Cisplatin | 1 | 2024 | 286 | 0.770 |
Why?
|
| Proton Therapy | 1 | 2024 | 156 | 0.770 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2022 | 1 | 0.740 |
Why?
|
| Hearing Loss | 1 | 2024 | 210 | 0.740 |
Why?
|
| Testicular Neoplasms | 2 | 2021 | 123 | 0.710 |
Why?
|
| Cerebellar Neoplasms | 1 | 2024 | 320 | 0.690 |
Why?
|
| Medulloblastoma | 1 | 2024 | 384 | 0.670 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.660 |
Why?
|
| Medical Oncology | 2 | 2021 | 237 | 0.660 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2022 | 163 | 0.650 |
Why?
|
| Pinealoma | 1 | 2020 | 20 | 0.640 |
Why?
|
| Pineal Gland | 1 | 2020 | 21 | 0.640 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1272 | 0.620 |
Why?
|
| Radiation, Ionizing | 1 | 2019 | 39 | 0.600 |
Why?
|
| Telecommunications | 1 | 2018 | 21 | 0.580 |
Why?
|
| Remote Consultation | 1 | 2018 | 26 | 0.570 |
Why?
|
| Head | 1 | 2019 | 115 | 0.560 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 260 | 0.560 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1356 | 0.560 |
Why?
|
| Carcinoma, Embryonal | 1 | 2017 | 1 | 0.550 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 55 | 0.550 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 48 | 0.530 |
Why?
|
| Immunoconjugates | 1 | 2017 | 49 | 0.530 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.520 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 295 | 0.520 |
Why?
|
| Neurology | 1 | 2018 | 121 | 0.500 |
Why?
|
| Teratoma | 1 | 2017 | 124 | 0.500 |
Why?
|
| Placenta | 1 | 2020 | 529 | 0.480 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 1255 | 0.480 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 500 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 366 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.460 |
Why?
|
| Down Syndrome | 1 | 2017 | 233 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 840 | 0.430 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 453 | 0.400 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 1809 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 1251 | 0.370 |
Why?
|
| Prognosis | 4 | 2024 | 4941 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 2114 | 0.340 |
Why?
|
| Pediatrics | 1 | 2018 | 1230 | 0.290 |
Why?
|
| Humans | 16 | 2025 | 131410 | 0.260 |
Why?
|
| Child | 6 | 2024 | 26224 | 0.250 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 25 | 0.220 |
Why?
|
| CD28 Antigens | 1 | 2025 | 75 | 0.220 |
Why?
|
| Retrospective Studies | 5 | 2024 | 17628 | 0.210 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2025 | 266 | 0.210 |
Why?
|
| Chemoradiotherapy | 1 | 2024 | 120 | 0.210 |
Why?
|
| Adolescent | 4 | 2024 | 20902 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 5267 | 0.200 |
Why?
|
| Female | 8 | 2024 | 71030 | 0.180 |
Why?
|
| Spinal Cord | 1 | 2023 | 266 | 0.180 |
Why?
|
| Chile | 1 | 2021 | 25 | 0.170 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 407 | 0.170 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3833 | 0.170 |
Why?
|
| alpha-Fetoproteins | 1 | 2021 | 139 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 86 | 0.160 |
Why?
|
| In Situ Hybridization | 1 | 2020 | 451 | 0.160 |
Why?
|
| Thrombosis | 1 | 2024 | 494 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2021 | 285 | 0.150 |
Why?
|
| Young Adult | 2 | 2024 | 10081 | 0.150 |
Why?
|
| Latin America | 1 | 2018 | 101 | 0.140 |
Why?
|
| Age Factors | 1 | 2024 | 2869 | 0.140 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2017 | 40 | 0.140 |
Why?
|
| Ki-1 Antigen | 1 | 2017 | 31 | 0.140 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 104 | 0.140 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2017 | 36 | 0.130 |
Why?
|
| Adrenalectomy | 1 | 2017 | 40 | 0.130 |
Why?
|
| Infratentorial Neoplasms | 1 | 2017 | 37 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2025 | 947 | 0.130 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3671 | 0.130 |
Why?
|
| Nephrectomy | 1 | 2017 | 174 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2024 | 15037 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2025 | 1775 | 0.120 |
Why?
|
| Infant | 3 | 2024 | 13292 | 0.120 |
Why?
|
| Internet | 1 | 2018 | 419 | 0.120 |
Why?
|
| Survivors | 1 | 2017 | 354 | 0.110 |
Why?
|
| Disease Management | 1 | 2019 | 562 | 0.110 |
Why?
|
| Survival Rate | 1 | 2020 | 2146 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 1159 | 0.100 |
Why?
|
| Adult | 2 | 2024 | 31628 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2025 | 4666 | 0.090 |
Why?
|
| Male | 4 | 2024 | 65108 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8584 | 0.090 |
Why?
|
| Prospective Studies | 1 | 2020 | 6481 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 4033 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 7571 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3909 | 0.060 |
Why?
|
| Thrombectomy | 1 | 2024 | 110 | 0.050 |
Why?
|
| Thrombolytic Therapy | 1 | 2024 | 207 | 0.050 |
Why?
|
| Aortic Diseases | 1 | 2024 | 189 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2017 | 12923 | 0.040 |
Why?
|
| Basal Ganglia | 1 | 2021 | 61 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 212 | 0.040 |
Why?
|
| Thalamus | 1 | 2021 | 87 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2024 | 594 | 0.040 |
Why?
|